Clinical Trial Update: Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy and safety of oral deferasirox in iron overload patients 3-6 months after allogeneic hematopoietic cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload

Drugs mentioned

• Deferasirox (Exjade) (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Iron Overload | Phase 4 | Status: COMPLETED